Slide 1: AdAlta investor presentation and Q&A conference call
ASX Announcement AdAlta investor presentation and Q&A conference call MELBOURNE Australia, 1 August 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to provide an updated presentation for the investor conference c
Slide 2: Notes to Editors: About AdAlta
Notes to Editors About AdAlta AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat dise
Slide 3: AdAlta SPP Presentation
AdAlta SPP Presentation August 2018 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au
Slide 4: Disclaimer
Disclaimer Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscript
Slide 5: AdAlta (1AD) investment summary
AdAlta (1AD) investment summary A drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases. Investment highlights Finalised Placement of $4.25m July 2018; la
Slide 6: Placement and SPP July 2018
Placement and SPP July 2018 Successfully closed $4.25m via Placement with institutional and high net worth in July 2018 Placement of 14,166,667 fully paid ordinary shares at a price of $0.30 per share – 14.3% discount to last traded price $0.35 – 16.7% discount to 15-day VWAP of $0.36 Directors inte
Slide 7: Financial position
Financial position Key financial details Share performance (last 12 months) ASX code 1AD Share price (31st July 2018) AU$0.30 Market capitalisation AU$34.65m Shares on issue* 115,490,062 Escrowed shares (August 2018) 24,047,138 Options on issue 3,734,471 Current cash (30th June 2018) AU$2.3m Trading
Slide 8: Extensive support from institutional investors and HNWs
Extensive support from institutional investors and HNWs Top 20 shareholders 80% Australian based venture capital $40m 61% institutional shareholders fund 11% HNWs with >500K shares each $27b under management, global 4% founding academic institutions equities investor 2.6% Board, SAB and Management a
Slide 9: Significant achievements 2017/18
Significant achievements 2017/18 ✓ Orphan Drug Designation (US FDA) of AdAlta i-body for treatment of IPF ✓ Completion of additional pre-clinical animal models in diseases of the lung, kidney, skin; strengthening broad anti-fibrotic data package of anti-CXCR4 i- body ✓ Publication of key data in Sci
Slide 10: AD-214 development: key milestones
AD-214 development: key milestones 2018 2019 2020 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Manufacturing Dosing and PK Toxicology Partnering of lead studies studies candidate based on other Phase I benchmark deals Publication of data Development of i-body pipeline BD and partnerships 8
Slide 11: Expected news flow
Expected news flow H1 2018 ✓ Publication of AD-114 data in Scientific Reports demonstrating i-body application of pulmonary fibrosis with human tissue and animal model data ✓ Investor and analyst briefing detailing application of the i-body for the undruggable targets such as GPCRs and ion channels
Slide 12: Share Purchase Plan
Share Purchase Plan Eligible Shareholders have the opportunity to participate in the Share Purchase Plan to subscribe for up to $15,000 (50,000) of new AdAlta shares The offer price per share under the SPP Offer will be 30 cents per share, being the same issue price as the Placement to institutional
Slide 13: AdAlta Limited (ASX: 1AD) summary
AdAlta Limited (ASX: 1AD) summary Successfully raised $4.25m in Placement with institutional and high net worth investors, completed post quarter’s end, securing funding for AD-214 to end of manufacturing SPP open now at same terms as Placement – closes on 10 August June cash position of $2.3m, with
Slide 14: Contact us
Contact us: Sam Cobb, CEO s.cobb@adalta.com.au www.adalta.com.au 12